anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hepatic fibrosis remains a significant clinical challenge due to ineffective treatments. 4-methylumbelliferone (4MU), a hyaluronic acid (HA) synthesis inhibitor, has proven safe in phase one clinical trials. In this study, we aimed to ameliorate liver fibrosis by inhibiting HA synthesis. We compared two groups of mice with CCl4-induced fibrosis, treated with 4-methylumbelliferone (4MU) and hyaluronan synthase 2 (HAS2) targeting siRNA (siHAS2). The administration of 4MU and siHAS2 significantly reduced collagen and HA deposition, as well as biochemical markers of hepatic damage induced by repeated CCl4 injections. The transcriptomic analysis revealed converging pathways associated with downstream HA signalling. 4MU- and siHAS2-treated fibrotic livers shared 405 upregulated and 628 downregulated genes. These genes were associated with xenobiotic and cholesterol metabolism, mitosis, endoplasmic reticulum stress, RNA processing, and myeloid cell migration. The functional annotation of differentially expressed genes (DEGs) in siHAS2-treated mice revealed attenuation of extracellular matrix-associated pathways. In comparison, in the 4MU-treated group, DEGs were related to lipid and bile metabolism pathways and cell cycle. These findings confirm that HAS2 is an important pharmacological target for suppressing hepatic fibrosis using siRNA.
Patients were selected prospectively for the study based on a 3-part algorithm used to identify rotator cuff tears at risk for retear. A total algorithm score of 3 or greater was required for enrollment in the study.
New methods for treating patients with a traumatic contusion-type spinal cord injury are provided. The method comprises the steps of providing a patient having a contusion-type injury and administering liposomes containing dichloromethylene diphosphonate (hereinafter referred to as "Cl 2  MBP") . The liposomes are preferably administered to the patient by intravenous injection. The liposomes are administered prior to the onset of infiltration of the spinal cord by the peripheral macrophages. Preferably, the liposomes are administered to the patient multiple times preferably during a period extending from 0 hours to seven days after occurrence of the injury. In a preferred embodiment, the liposomes are multilamellar phosphatidylcholine liposomes.
Once enrolled in study, the subject will be put in one of 2 groups by chance (as in the flip of a coin). They will either receive methylphenidate or a placebo. Everyone in study will receive nicotine dependence counseling based on the intervention manual "Smoke Free and Living It". Everyone will be asked to complete weekly study visits for 8 weeks and one follow-up phone call at week 16 and a final study visit at week 24. The target quit day is the day after visit 4 (week 2 + 1 day). In the first two weeks after starting study medication they will slowly build up to 3 pills a day. For weeks 2 through 8 they will continue to take 3 pills a day.
UNLABELLED: Coronavirus disease 2019 (COVID-19) and cancer are major health threats, and individuals may develop both simultaneously. Recent studies have indicated that patients with cancer are particularly vulnerable to COVID-19, but the molecular mechanisms underlying the associations remain poorly understood. To address this knowledge gap, we collected single-cell RNA-sequencing data from COVID-19, lung adenocarcinoma, small cell lung carcinoma patients, and normal lungs to perform an integrated analysis. We characterized altered cell populations, gene expression, and dysregulated intercellular communication in diseases. Our analysis identified pathologic conditions shared by COVID-19 and lung cancer, including upregulated TMPRSS2 expression in epithelial cells, stronger inflammatory responses mediated by macrophages, increased T-cell response suppression, and elevated fibrosis risk by pathologic fibroblasts. These pre-existing conditions in patients with lung cancer may lead to more severe inflammation, fibrosis, and weakened adaptive immune response upon COVID-19 infection. Our findings revealed potential molecular mechanisms driving an increased COVID-19 risk in patients with lung cancer and suggested preventive and therapeutic targets for COVID-19 in this population.
IMPLICATIONS: Our work reveals the potential molecular mechanisms contributing to the vulnerability to COVID-19 in patients with lung cancer.
An integral, one-piece silanated particle impregnated gutta percha core/cone technique employs a thin layer of a luting agent, such as glass ionomer cement with a machined gutta percha core/cone (10), precisely matches the preparation, thereby reducing leakage and achieving a hermetic seal. The hermetic seal is further enhanced by a mono-block bond that occurs between the silanated particles in the gutta percha and the appropriate chemical sealant. Optional cryogenic treatment of the gutta percha material changes its molecular weight, making it stiffer and conducive to forming an integral, one piece core/cone, without the need for a separate carrier core to install the tapered gutta percha core/cone (10) within the root canal. Additionally, the tapered body of the core/cone may be reticulated in a slightly three dimensional texturized framework (20) to increase surface area and therefore increase retention. Optional line demarcation indicia (14a) are also placed on the core/cone. Additionally, the head (12) of the core/cone can be gripped by a delivery vehicle clasp.
BACKGROUND AND OBJECTIVES: Zagotenemab (LY3303560), a monoclonal antibody that preferentially targets misfolded, extracellular, aggregated tau, was assessed in the PERISCOPE-ALZ phase 2 study to determine its ability to slow cognitive and functional decline relative to placebo in early symptomatic Alzheimer disease (AD).
METHODS: Participants were enrolled across 56 sites in North America and Japan. Key eligibility criteria included age of 60-85 years, Mini-Mental State Examination score of 20-28, and intermediate levels of brain tau on PET imaging. In this double-blind study, participants were equally randomized to 1,400 mg or 5,600 mg of zagotenemab, or placebo (IV infusion every 4 weeks for 100 weeks). The primary outcome was change on the Integrated AD Rating Scale (iADRS) assessed by a Bayesian Disease Progression model. Secondary measures include mixed model repeated measures analysis of additional cognitive and functional endpoints as well as biomarkers of AD pathology.
RESULTS: A total of 360 participants (mean age = 75.4 years; female = 52.8%) were randomized, and 218 completed the treatment period. Demographics and baseline characteristics were reasonably balanced among arms. The mean disease progression ratio (proportional decline in the treated vs placebo group) with 95% credible intervals for the iADRS was 1.10 (0.959-1.265) for the zagotenemab low-dose group and 1.05 (0.907-1.209) for the high-dose, where a ratio less than 1 favors the treatment group. Secondary clinical endpoint measures failed to show a drug-placebo difference in favor of zagotenemab. No treatment effect was demonstrated by flortaucipir PET, volumetric MRI, or neurofilament light chain (NfL) analyses. A dose-related increase in plasma phosphorylated tau181 and total tau was demonstrated. Zagotenemab treatment groups reported a higher incidence of adverse events (AEs) (85.1%) compared with the placebo group (74.6%). This difference was not attributable to any specific AE or category of AEs.
DISCUSSION: In participants with early symptomatic AD, zagotenemab failed to achieve significant slowing of clinical disease progression compared with placebo. Imaging biomarker and plasma NfL findings did not show evidence of pharmacodynamic activity or disease modification.
TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov: NCT03518073.
CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with early symptomatic AD, zagotenemab does not slow clinical disease progression.
Children allocated to this arm will receive skin dressings made out of human amniotic membrane. Dressings will be replaced every 72 - 96 hours.
Patients will be treated by one cure of TACE at week 0. Then, patients will be treated within two weeks by external conformational radiotherapy of 54 grey fractioned in 18 sessions during 3-4 weeks.
External beam radiotherapy (hypofractionated or conventionally fractionated) at a biologically effective dose converted to 2Gy fractions (α/β:1.5) of at least 76Gy. EBRT may be combined with a brachytherapy boost and PLND may be performed for staging purposes. The presence of positive lymph nodes (pN1) upon PLND is not a reason for exclusion and lymph node irradiation may be performed. Patients should receive ADT for at least 6 months.
Participants will self-serve and condiment a cold meal in the laboratory using standard kitchen utensils, including 2 nylon serving spoons and a simple glass oil dispenser. Participants will complete an eye-tracking test before eating, and will fill in questionnaires and provide blood samples during and after the meal. At 2h post-meal, they will complete a computerized memory reconstruction task related to the meal. After leaving the laboratory participants will keep a food diary, and will complete an on-line learning test before bedtime.
FIELD: medicine, biochemistry. SUBSTANCE: method involves insulin interaction with proteinase protein inhibitors in an aqueous solution in the presence of cross-linking agent. Ovomucoid from duck eggs is used as protein inhibitor of proteinase. Method ensures to obtain insulin derivatives activity of that at oral administration are equal to the parental insulin activity at subcutaneous administration. These insulin derivatives can be used as medicinal agent for treatment of patients with diabetes mellitus. EFFECT: improved method of insulin preparing. 2 cl
It is a paradox that medical efforts to control blood glucose in type 2 diabetes mellitus have not decreased the risk of cardiovascular disease. Postprandial lipid concentrations are a strong predictor of cardiovascular risk, independent of traditional cardiovascular risk factors. The new classes of antidiabetic medications - GLP-1 agonists and DPP-IV inhibitors - affect lipid as well as glucose metabolism. This study will investigate the efficacy of these medications in reducing postprandial hyperlipidemia, disrupting the concurrent proinflammatory free fatty acid signaling, and ameliorating endothelial dysfunction in individuals with prediabetes. This will consist of a single center, randomized, crossover, placebo-controlled double-blinded prospective trial involving three study arms representing the aforementioned medications: exenatide (GLP-1 agonist), saxagliptin (DPP-IV inhibitor), and placebo (control arm). Each subject will participate in each of the three arms, which are three separate, daylong outpatient studies. For each study arm, subjects will eat a standardized atherogenic high-fat test lunch. Venous blood draws and measurements of forearm blood flow will be done prior to the meal and periodically during a 6-hour period after the meal. Forearm blood flow measurements will assess for changes in endothelial function. The blood will be analyzed for multiple markers of hyperlipidemia and free fatty acid signaling. After completing the three randomized study visits, subjects are invited to participate in an optional, nonrandomized extension study. For the extension study, subjects will take exenatide ER (extended-release exenatide) weekly for total of six weeks. Then subjects return to eat a standardized atherogenic high-fat test lunch. Venous blood draws and measurements of forearm blood flow will be done prior to the meal and periodically during a 4-hour period after the meal, for the same analyses described before. The results will provide new insights into the anti-inflammatory effects of multiple antidiabetic medications via the mechanisms of postprandial hyperlipidemia, free fatty acid signaling, and endothelial function in prediabetic individuals.
Disclosed is a preparation method for extracting dihydro quercetin from larch. The invention is an improved production method. Due to different production materials and extraction processes, the dihydro quercetin products in U.S. and European markets are very expensive, at a price of 200-1000 euros per gram. Such a high market price economically limits the wide range of practicability of dihydro quercetin products. During the pretreatment of raw materials, 50 kilograms of larch wood chips and 500-800 liters of 50% ethanol solution are added into an extractor to get fully stirred and mixed; then the mixture is extracted and filtered for the second extraction; the filtrates are combined and adsorbed; the organic solvents are collected and dried by a vacuum evaporator through organic phase vacuum distillation; according to a weight proportion of 10:1, the residues are dissolved with hot water, decolorized with activated carbon and then crystallized at a temperature of 3-5 DEG C to precipitate the dihydro quercetin product which is then crushed after vacuum drying to finished product. The invention is used to extract dihydro quercetin from larch.
Participants assigned to Usual Care (n=50) will receive standard care. MSK's current usual care for distress screening is that all patients are screened for distress when they initiate care at MSK. Additional distress screening is conducted based on the determination of the oncology team. In addition, patients are referred to social work, psychology, and/or psychiatry based on the judgment of the oncology team.
Patients who are on drugs that suppress the immune system are more susceptible to infection than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In children or adults who have not had these diseases, or been properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, therapy with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents may be considered. 

The clinical course of chicken pox or measles infection in patients on inhaled corticosteroids has not been studied. However, a clinical study has examined the immune responsiveness of asthma patients 12 months to 8 years of age who were treated with PULMICORT RESPULES. An open-label non-randomized clinical study examined the immune responsiveness of varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with PULMICORT RESPULES 0.25 mg to 1 mg daily (n=151) or noncorticosteroid asthma therapy (n=92) (i.e., beta2-agonists, leukotriene receptor antagonists, cromones). The percentage of patients developing a seroprotective antibody titer of ≥5.0 (gpELISA value) in response to the vaccination was similar in patients treated with PULMICORT RESPULES (85%) compared to patients treated with non-corticosteroid asthma therapy (90%). No patient treated with PULMICORT RESPULES developed chicken pox as a result of vaccination. 

Inhaled corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract, untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.
A survey with cross-sectional design was applied in 829 older Mexican adults, recruited during the period July to September 2015, from four localities in the southern region of México: including Champotón, Campeche, Mérida, and Valladolid. Older adults were interviewed at their homes to collect nutrition, health, cognitive and dietary information. Anthropometric measures and functionallity tests were also collected. A finger prick capillary blood sample was collected to measure hemoblobin in situ using HemoCue. Anemia was defined according to WHO criteria. A fasting venous blood sample was collected in 803 older adults. Serum was separated and frozen at -20°C to measure ferritin, retinol, vitamin B12, folate, iron, soluble transferrin receptor, C-reactive protein, interleukin 6, alpha glycoprotein 1, hepcidin, erythropoietin in the laboratory of nutrition of the National Institute of Public Health.

The study protocol was approved by Research, Biosecurity and Ethics Committees of the National Institute of Public Health. Participants received a detailed explanation of the study procedures and signed an informed consent form prior to data collection.
The present invention is a system and method for facilitating the process of caring for an individual, such as an elder. The present invention also disseminates a wide range of information to users. The system allows members of an elder's support group to easily and conveniently communicate and coordinate their actions. The present invention is accomplished by the creation of an “e-space” for the elder. The e-space is a set of data files that are associated with the elder. The e-space is stored in a central location that can be accessed conveniently by individuals by accessing a computer network such as the Internet. The system also allows the elder (or an agent of the elder called a “responsible party”) to maintain his or her privacy by controlling access to his or her e-space. This is accomplished by providing the elder or responsible party the ability to specify varying levels of access privileges for each type of data file in his/her e-space for each member of his/her support group. The system also allows the elder to delegate privileging power to an administrator or official at the care provider facility where he or she is residing. The administrator/official can then grant access privileges to members of the care provider staff The system also provides a variety of information and tools which assist individuals in making decisions related to elder care.
It is thought that Negative Pressure Wound Therapy may have numerous mechanisms of action when used to manage surgical incisions, including reducing oedema, stimulating perfusion and managing exudate. Post-operative oedema in the peri-wound tissue is thought to limit tissue perfusion and high levels of wound fluid loss have been correlated with increased risk of post-operative infection and dehiscence23. Application of NPWT to the closed wound has been reported to improve patient comfort through reduced dressing changes and to lessen the period during which post-operative fluid discharges from the incision. Xia et al (2014)24 demonstrated that in 20 patients with infected wounds, NPWT resulted in significantly increased blood flow in the wounds when compared to pre application levels. In a study by Young et al (2013)25 four patients with pressure ulcers had oedema and wound bed thickness assessed during follow-up. They demonstrated a rapid reduction of peri-wound tissue oedema over four days and a 20% increase in the thickness of the wound bed by seven days of therapy.

Risk factors such as smoking and obesity have shown to increase complications follow oncoplastic surgery26 and it is possible that such populations could benefit more from the application of the NPWT. Furthermore there are a number of bilateral or multi wound indications where provision of a single device with the Y connection may represent a cost saving to the healthcare system. However, ultimately the use of NPWT for oncoplastic breast surgery closed incisions will be judged on whether it can increase the healing success rate while minimising complications. Holt and Murphy (2015)27 assessed the use of PICO single use NPWT system when applied to 24 patients with closed incisions following therapeutic resection. The contralateral breast underwent simultaneous symmetrising breast reduction with standard care dressings applied allowing for direct comparison. Although the cohort was too small to draw meaningful statistical conclusions they noted a lower incidence of wound breakdown (4.2% vs. 16.7%) and shorter time to healing (10.7 days vs. 16.1 days) in the NPWT group. However, this difference was partly attributed to the more extensive and complex nature of the therapeutic surgery. Similarly in a category of patients undergoing breast surgery with primary wound closure, Pellino et al (2014)19 showed significantly lower surgical site events when treated with PICO.
The invention relates to an orchid handmade soap and a preparation method therefor and belongs to the technical field of daily use chemical washing and protection products. The orchid handmade soap is prepared from orchid extractive, propylene glycol, sodium silicate, lauryl dimethyl betaine, soap pulp, coconut oil, stearic acid and deionized water at certain weight ratios. The orchid handmade soap can be used for cleaning of faces and bodies directly. When the orchid handmade soap is used, abundant foams are formed directly, and positions to be cleaned can be cleaned. The orchid handmade soap can clean deep skin dirt, is mild and has no stimulation. The orchid handmade soap has functions of nourishing, water supplementing, restoring and the like, and is a washing and protection product which can be used for a long time.
Usual diabetes care for 18 months, which consists of visits with their health care provider and ad-hoc diabetes education with nurses and dietitians. Health care providers from the pediatric diabetes clinics will be instructed not to discuss or refer to the Support-t platform with patients from the control arm. Control arm participants will have the option to use the Support-t platform after the 18-month study.
Allopurinol is known chemically as 1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one. It is a xanthine oxidase inhibitor which is administered orally. It is available in 100 mg and 300 mg strengths. The 100mg tablets contain the inactive ingredients lactose, magnesium stearate, potato starch, and povidone. The 300mg tablets contain the inactive ingredients lactose, magnesium stearate, corn starch, and povidone. Its solubility in water at 37°C is 80.0 mg/dL and is greater in an alkaline solution.

Allopurinol has the following structural formula:
A composition comprises at least two different powders each comprising ω-3 fatty acids. A first of the powders is hoki roe (HR) powder present at 5% w/w. The HR powder preferably provides at least 3.3% of the total ω-3 fatty acids in the composition and/or may be present in an amount from 5-95% w/w of the composition mass. The HR powder may comprise a total fat content of 14-40% and/or may comprise a total ω-3 fatty acid content of 2-20%. A second of the powders is preferably green-lipped mussel (GLM) powder. The GLM powder may comprise a total fat content of 7-13% and/or may comprise a total fatty acid content of 2.0-5.0%. The composition may be provided as a foodstuff, nutraceutical or supplement, and may be for use in maintenance of health of a human or animal, preferably for maintaining joint health and/or involving support of anti-inflammatory pathways. The foodstuff or supplement may include one or more excipients such as Glucosamine and/or Hyaluronic Acid. Methods of maintaining joint health and of modulating anti-inflammatory pathways are also claimed, the methods comprising administering the claimed composition to an animal or human in need of the composition.